Genentech gets gluey, paying $47M upfront to Orionis for degrader discovery deal
In its second deal announced Wednesday morning, Roche’s Genentech is signing up with Orionis Biosciences for a molecular glue partnership in cancer and neurodegeneration.
Genentech will pay Orionis $47 million upfront, and it’s promised over $2 billion in potential downstream milestones. Orionis, a biotech company based out of Boston and Ghent, Belgium, plans to discover and optimize small molecule molecular glues for certain undisclosed targets for Genentech, which will then take over preclinical and clinical development of the drug candidates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.